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Objective: to study the influence of serologically diagnosed chronic infection with Chlamydia pneumoniae on the
progression of lower limb atherosclerosis in a group of disposed men.
Material and methods: the highest systolic brachial and lowest systolic ankle blood pressures were followed for an
average of 2.7 years in 129 men aged 65–73 years with conservatively treated small abdominal aortic aneurysms. Blood
samples were taken to measure low-density lipoprotein and IgA and IgG titres of antibodies against C. pneumoniae by
a microimmunofluorescence test.
Results: the prevalences of seropositivity varied from 43 to 83% depending on the definition. The ankle–brachial blood
pressure index of the IgA-seronegative men decreases by 11%, while it decreased by 4.8% among IgA-seronegative men
(p<0.05). The significant difference persisted in a multiple-regression analysis adjusting for age, smoking, initial systolic
ankle BP, and initial brachial systolic or diastolic BP, but disappeared after adjusting for the level of low-density
lipoprotein.
Conclusions: C. pneumoniae infection is associated with the progression of atherosclerosis.
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Introduction impact of detecting the organism is unresolved. Con-
sequently, we have studied the influence of sero-
Several serological studies have demonstrated an as- logically diagnosed chronic infection of C. pneumoniae
on the progression of lower-limb atherosclerosis in asociation between Chlamydia pneumoniae and the risk
of acute myocardial infarction.1–7. Furthermore, studies group of disposed men.
have detected C. pneumoniae DNA and C. pneumoniae
antigen in atherosclerotic lesions from coronary and
carotid arteries and abdominal aortic aneurysms.8–15
However, culture of C. pneumoniae has only succeeded Material and methods
twice.16,17 Two controlled clinical trials randomised
patients with ischaemic heart disease to antibiotic A randomised screening trial for abdominal aortic
aneurysm (AAA) in 65–73-year-old men was startedtreatment or placebo.18,19 Both trials showed a sig-
nificant reduction in serious end-points concerning in 1994 in Viborg County, Denmark (n=13000). From
1994 to 1996, a small AAA was diagnosed in 149ischaemic heart disease among patients receiving mac-
rolides. However, the trials were small, and it is not men. They were initially offered a consultation for
information, interview, and examination. Based uponknown whether this was caused by eradicating C.
pneumoniae organisms, or by the known non-specific the interview, smoking habits were classified according
to present smoking status, i.e. previous smokers wereanti-inflammatory effect of macrolides.20 Furthermore,
there might exist a pathogenetic factor promoting both classified as non-smokers. The systolic blood pressures
(BP) were measured on each arm, and the highestan increased low-density-lipoprotein accumulation
with accelerated atherosclerosis, and an increased sus- pressures were recorded. The systolic ankle BP was
measured at each ankle with the use of Doppler tech-ceptibility to chronic C. pneumoniae infection. Thus,
the pathogenicity remains unknown, and the clinical nique, and the lowest value was recorded. The ankle
BP index (ABPI) was calculated as systolic ankle BP/
the arm systolic BP.* Please address all correspondence to: J. S. Lindholt, Laerkevej 11,
8900 Randers, Denmark. Serum samples were used to measure low-density
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Table 1. Prevalences of seropositivity of Chlamydia pneumoniae compared to the change in
ankle blood pressure index (ABPI).
n=129 Prevalence Mean ABPI Mean decrease
No/Yes ABPI No/Yes
Percent 95% CI
Iga[40 43 34–52 96.9/99.1 6.8/10.4
IgG[64 56 47–65 96.2/99.4 6.3/10.2
IgA[40 or IgG[64 62 53–71 96.7/98.7 5.5/10.5
IgA[20 68 59–77 96.5/98.7 4.8/10.6*
IgG[32 75 66–83 97.2/98.1 4.3/10.2
IgA[20 or IgG[32 83 74–89 96.5/98.3 3.9/9.9
No/Yes: Concerning seropositivity defined as a titre equal to or above the present tested titre.
ABPI: Ankle blood pressure index (Systolic ankle blood pressure/arm blood pressure).
* p<0.05 (unpaired t-test).
Table 2. Multivariate regression analyses with and without the level of low density lipoprotein (LDL)
as independent variable and decrease in ABPI as dependent variable.
Independent variable Mean B-coefficient B-coefficient
IgA[1:20 (Yes=1, No=0) 0.58 5.639 (0.145–11.113) 2.960 (-4.975–10.895)
Age (years) 68.1 -0.282 (-1.260–0.696) -0.538 (-2.032–0.956)
Smoking (Yes=1, No-0) 0.65 -1.660 (-7.313–3.993) -2.752 (-10.364–4.860)
Systolic ankle BP (mmHg) 154.5 0.175 (0.099–0.250) 0.210 (0.109–0.312)
Diastolic arm BP (mmHg) 93.0 -0.032 (-0.261–0.198) -0.161 (-0.341–0.019)
LDL (mmol/l) 1.11 0.212 (-7.336–7.759)
Y-intercept 1.197 38.523
lipoprotein (LDL) and IgA and IgG antibodies for C. was 153.5 mmHg (s.d.: 39.3), and the mean ABPI was
0.97 (s.d.: 0.24). 13.5% had complaints of intermittentpneumoniae by a microimmunofluorescence test con-
ducted by one experienced technician,21 who is per- claudication. The arithmetical (Bland & Altmann)
interobserver variation22 of the ABI measurements wasforming the test frequently because of employment at
the only laboratory in Denmark that performs the 0.16. Pearson’s correlation of the interobserver meas-
urements was 0.98.test.21 The lowest dilutions used were 1:20 and 1:
32 concerning IgA and IgG antibodies, respectively. The prevalences of seropositivity varied from 43 to
83%, depending on the definition; 58% (95% CI: 49–Consequently, IgA and IgG seronegatives were defined
as those without detectable IgA- and IgG-antibodies 67%) had IgA titre of 1:20 or more, 62% (53–71%) had
IgA[40 or IgG[64, and 83% (74–93%) had IgA[20 orat these respective dilutions.
The men with small AAAs were followed by annual IgG[32. No statistical differences were found between
the various titre groups, observation time, and ABPI.follow-up in outpatient clinics at all five hospitals in
the country of Viborg. The lowest ABPI were recorded. However, ABPI of the IgA seropositive men decreased
11%, while that of the seronegative men decreasedOne-hundred and twenty-nine were followed by two
observers for one to three years (mean 2.7 years). The by 4.8% (p<0.05) (Table 1). This significant difference
persisted in multiple-regression analysis adjusting forreasons for not seeing the remaining cases was death
in about half of the cases, and the development of age, smoking, initial systolic ankle BP, initial arm
systolic or diastolic BP but disappeared after adjustingserious illness, mainly stroke, in the rest, except in
two cases who rejected follow-up because of anxiety. for the level of LDL (Table 2).
Unpaired t-tests, and multivariate linear regression
analyses were used in the statistics. The arithmetical
method described by Bland and Altman22 and
Pearson’s correlation test were used for validation of Discussion
the ABPI measurements.
Our study demonstrated a very high prevalence of
seropositivity of C. pneumoniae, varying from 43 to
83% depending on the definition. Saikku et al.1 foundResults
that 50% of 40 males with acute myocardial infarction,
68% of 30 males with angina pectoris, but only 17%The mean systolic arm blood pressure was
158.7 mmHg (s.d.: 21.1), the mean systolic ankle BP of 41 matched controls, had elevated levels of IgG and
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demonstrated coronary artery disease. Arterioscler Thromb 1991;IgA-antibodies against C. pneumoniae. Traditionally,
11: 547–551.the cut-off point for defining a chronic or acute in- 5 Thom DH, Grayston JT, Siscovick DS et al. Association of
prior infection with Chlamydia pneumoniae and angiographicallyfection has been an IgA titre of 40 or more, or an IgG
demonstrated coronary disease. JAMA 1992; 268: 68–72.titre of 64 or more. However, IgA antibodies are short-
6 Linnanma¨ki E, Leinonen M, Matilla K et al. Chlamydia pneu-lived and the presence of even smaller concentrations moniae-specific circulating immune complexes in patients with
chronic coronary heart disease. Circulation 1993; 87: 1130–1134.than 1:40 may be a sign of recent or present infection.
7 Melnick ST, Shahar E, Folsom AR et al. Past infection byConsequently, a cut-off point of half the dilution tra-
Chlamydia pneumoniae stain TWAR and asymptomatic carotidditionally used was made, and all performed tests stenosis. Am J Med 1993; 95: 499–504.
8 Kuo CC, Shor A, Campbell LA et al. Demonstration of Chlamydiashowed that an IgA titre of 20 or more was associated
pneumoniae in arteriosclerotic lesions of coronary arteries. J Infectwith a significantly decrease in ABPI. However, the
Dis 1993; 167: 841–849.significance level is just below 5%, and the use of tests 9 Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae
in coronary arterial fatty streaks and atheromatous plaques. Sconcerning the other cut-off points could argue for a
Afr Med J 1992; 82: 158–161.need to correct for multiple statistical comparisons.
10 Kuo CC, Grayston JT, Campbell LA et al. Chlamydia pneumoniaeOn the other hand, the initial idea was to use a lower (TWAR) in coronary arteries of young adults (15–34 years old).
Proc Natl Acad Sci USA 1995; 92: 6911–6914.IgA cut-off point for reasons mentioned above. Finally,
11 Campbell LA, O’Brien ER, Cappuccio AL et al. Detection ofall the performed tests tended towards a faster decline
Chlamydia pneumoniae TWAR in human coronary atherectomyin ABI among those with a positive titre. An in vitro tissue. J Infect Dis 1995; 172: 585–588.
12 Muhlestein JB, Hammond EH, Carlquist JF et al. Increasedstudy demonstrated an increase in the number of foam
incidence of Chlamydia pneumoniae species within the coronarycells and accumulation of cholesterol esters occurred
arteries of patients with symptomatic atherosclerosis versus otherwhen C. pneumoniae was propagated in presence of forms of cardiovascular disease. J Am Col Cardiol 1996; 27:
1555–1561.LDL, but these changes were inhibited by application
13 Grayston JT, Kuo CC, Coulson AS et al. Chlamydia pneumoniaeof heparin, which blocks the binding of LDL to its
(TWAR) in atherosclerosis of the carotid artery. Circulation 1995;receptors.23 92: 3397–3400.
14 Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection ofIn conclusion, our observations suggest that chronic
Chlamydia pneumoniae in aortic atherosclerotic lesions by im-infection with C. pneumoniae plays a part in the pro-
munocytochemical stain. Arterioscler Thromb 1993; 13: 1501–1504.gression of lower-limb atherosclerosis, and they sup- 15 Ong G, Thomas BJ, Mansfield AO, Davidson BR,
Taylor-Robinson D. Detection and widespread distributionport the in vitro study suggesting an LDL-dependent
of Chlamydia pneumoniae in the vascular system and itsmechanism. Macrolides may improve the prognosis
possible implications. J Clin Pathol 1996; 49: 102–106.of symptomatic lower-limb atherosclerosis. 16 Ramirez JA. The Chlamydia pneumoniae/Atherosclerosis study.
Isolation of Chlamydia pneumoniae from the coronary artery of a
patient with coronary atherosclerosis. Ann Intern Med 1996; 125:
979–982.
17 Jackson LA, Campbell LA, Kuo CC et al. Isolation of ChlamydiaAcknowledgements pneumoniae from a carotid endarterectomy specimen. J Infect Dis
1997; 176: 292–295.
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